# Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

> **NCT05912621** · PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 66 (estimated)

## Conditions studied

- Obesity
- Overweight and Obesity
- Overweight

## Interventions

- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT05912621
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2028-06
- **Final completion:** 2029-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05912621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05912621, "Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05912621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*